Video: NIAID Ebola vaccine well tolerated, immunogenic
WILMINGTON, Del. — Julie Ledgerwood, DO, of the National Institute of Allergy and Infectious Diseases' Vaccine Research Center, reviews progress on development of the cAd3-EBO vaccine, presented today at the New Technologies, New Vaccines 2015 conference.
Ledgerwood said that the recombinant vaccine, which was rapidly advanced into Phase 1 clinical evaluation, was well tolerated and demonstrated immunogenicity.
Disclosure: Ledgerwood reports no relevant financial disclosures.